A study published in the peer-reviewed journal Molecular Biology Reports has “demonstrated that cannabidiol is a viable therapy to treat prostate cancer cells”.
Prostate cancer is the second most frequently occurring carcinoma in males worldwide and one of the leading causes of death in men around the world, states the study which was conducted by researchers at the Department of Biochemistry at the University of Johannesburg in South Africa. Recent studies estimate that over 1.4 million males are diagnosed with prostate cancer on an annual basis, with approximately 375,000 succumbing to the disease annually.
With current treatments “continuing to show severe side effects”, researchers say there is a need for new treatments. In this study they “looked at the effect of cannabis sativa extract, cannabidiol and cisplatin on prostate cancer cells, PC3.”
In addressing the above questions, researchers “employed the MTT assay to measure the antiproliferative effect on PC3 cells following treatment with varying concentrations of Cannabis sativa extract, cisplatin and cannabidiol.”
Further explaining their methodology, researchers state:
xCELLigence was also used to confirm the IC50 activity in which cells were grown in a 16 well plate coated with gold and monitor cell attachment. Caspase 3/7 activity was also measured using 96 well-plate following treatment. Western-blot and qRT-PCR was also used to measure the gene expression of tumour suppressor genes, p53, Bax and Bcl2. Animal studies were employed to measure the growth of PC3-mouse derived cancer to evaluate the effect of compounds in vivo.
From the treatment with varying concentrations of cannabis sativa extract, cannabidiol and cisplatin, “we have observed that the three compounds induced antiproliferation of PC3 cancer cell lines through the activation of caspase 3/7 activity.” Researchers also observed “induction of apoptosis in these cells following silencing of retinoblastoma binding protein 6 (RBBP6), with upregulation of p53 and bax mRNA expression, and a reduction in Bcl2 gene expression.”
Specifically, “The growth of tumours in the mouse models were reduced following treatment with cisplatin and cannabidiol.”
The study concludes by stating that researchers “demonstrated that cannabidiol is a viable therapy to treat prostate cancer cells, in combination with silencing of RBBP6. This suggests that cannabidiol rather Cannabis sativa extract may play an important role in reducing cancer progression.”
For more information on this study you can click here.
